EDE Edenville

    15 January 2008

                         Eden Research plc ("Eden Research" or the "Company")
                                                   
                             Exercise of warrants and loan note agreement
                                                   
Exercise of warrants

Eden  Research is pleased to announce that it has issued 1,490,261 Ordinary Shares of 1p each pursuant
to  the  exercise  of  warrants.  The net proceeds to the Company from this exercise  of  warrants  is
�390,356.

Loan Note Agreement

Separately,  Eden Research has entered into a �750,000 convertible loan note agreement with  Trafalgar
Capital Specialized Investment Fund (the "Lender").

The loan carries interest at a commercial rate and is for a two year period but is repayable early  by
the Company, subject to early redemption costs.  Additionally, the Lender has the right to convert  up
to  �50,000 per week of the then outstanding debt (if not repaid) into ordinary shares at the lower of
115%  of the share price on 31 December 2007 or a 15% discount to the prevailing price at the time  of
conversion. These conversion rights only begin in February 2008.

The  loan  is structured so that �500,000 was forwarded to the Company on 31 December 2007,  with  the
balance of �250,000 available on 1 September 2008 to the Company if requested.  The loan is to be used
for  general  working capital purposes and could be used for acquisitions, yet to  be  identified,  if
considered appropriate.

As  part of the agreement, the Company issued to the Lender warrants over 575,000 Ordinary shares with
a  term  of  5 years and an exercise price for 50% at the price of the Ordinary Shares on 31  December
2007 and for 50% at 115% of that price.

Additionally  the  Lender  was  issued with 24,800 Ordinary Shares as a  facility  commitment  fee  on
entering  into  the agreement and the Company has paid various further commitment, due  diligence  and
structuring fees in respect of the loan.

Piers Linney, a partner at Trafalgar Capital said "We are pleased to have the opportunity to invest in
the Company and we were attracted by the management team and the market potential of the products".

Tim Griffiths the Chief Executive of Eden Research said "This latest warrant exercise demonstrates  an
increasing  confidence  with regard to the future and the Trafalgar commitment will help  the  Company
accelerate significantly  its development programme".


Ends

For further information, contact:

Tim Griffiths, Chief Executive, Eden Research plc
T: 01993 868844

Jonathon Brill/Caroline Stewart, Financial Dynamics
T: 020 7831 3113


About Eden Research plc

Eden  Research plc is a UK publicly listed company on the PLUS Market, specialising in the development
of agrochemical products and intellectual property through licensing and marketing agreements.

Eden  is focused on developing products for the agricultural sector through the application of terpene
chemistry  and  other  patented  environmentally friendly technologies.   Eden  is  currently  working
alongside   universities   and  partner  companies  in  developing  its  product   portfolio   towards
commercialisation.

For further information please visit www.edenresearch.com.

                                                                
Eden Research Plc



                                                                

Edenville (LSE:EDE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Edenville (LSE:EDE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024